



qi lu ORCID iD: 0000-0002-5428-4032

Coronavirus disease (COVID-19) and neonate: What neonatologist need to know

Qi Lu^{MD,PhD}, Yuan Shi^{MD,PhD}

Department of Neonatology, Children's Hospital, Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Key Laboratory of Pediatrics in Chongqing, Chongqing, China Chongqing 400014, China

Abstract:

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cause china epidemics with high morbidity and mortality,the infection has been transmitted to other countries. About 3 neonates and more than 230 children cases are reported. The disease condition of mainly children was mild. There is currently no evidence that SARS-CoV-2 can be transmitted transplacentally from mother to the newborn. The treatment strategy for children with Coronavirus disease (COVID-19) is based on adult experience. Thus far, no deaths have been reported in the paediatric age group. This review describes the current understanding of COVID-19 infection in newborns and children.

Since December 2019, patients with fever, dry cough, normal or decreased white blood cell counts who were initially diagnosed as " Fever of Unknown Origin with pneumonia " have been continuously increasing in Wuhan[1]. The causative agent of this unexplained infected pneumonia was identified as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which not only has a strong human-to-human transmission, but also causes severe pneumonia to death[2]. SARS-CoV-2 is so aggressive that the infection has been transmitted to other countries and is seriously imperilling human life. WHO has declared this disease to constitute a Public Health Emergency of International Concern on 30 January 2020 [3]. A total of

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jmv.25740.

This article is protected by copyright. All rights reserved.

Accepted Article

26359 suspected cases and 31225 confirmed cases with 639 deaths linked to this pathogen on February 7, 2020[4]. Different age groups are generally susceptible to SARS-CoV-2. At present, neonates have been diagnosed with Coronavirus disease (COVID-19). Neonatologists should be vigilant assessing newborn babies delivered by infected mothers or brought up by infected housemaids and improve the knowledge of prevention and treatment of COVID-19.

Etiology of COVID-19.

SARS-CoV-2 is a single stranded RNA virus, belongs to the subgenus Sarbecovirus of the genus Betacoronavirus[5]. SARS-CoV-2 particles contain spike and envelope, virions are spherical, oval, or pleomorphic with diameters of approximately 60-140 nm. Culture times were 4 days on human airway epithelial cell lines and 6 days on Vero E6 / Huh-7 cell lines. The ssRNA was 29,903 bp in length. The organization of the SARS-CoV-2 genome is 5' -leader-UTR-replicase-S (Spike) - E (Envelope)-M (Membrane)-N (Nucleocapsid)-3' UTR-poly (A) tail with unknown open reading frames[6]. Its reference sequence (NC_045512.2) is with 80.26% sequence identity (and query coverage above 98%) to the human Severe acute respiratory syndrome (SARS) coronavirus genome (NC_004718.3) [7], however Middle East respiratory syndrome (MER) coronavirus is lower related to SARS-CoV-2 which is a group 2c β -coronavirus. SARS-CoV-2 exhibits very high sequence similarity to the Guangdong pangolin coronaviruses in the receptor-binding domain which indicates pangolins may be an intermediate host of the virus before dissemination to humans [8]. SARS-CoV-2 has weak resistance, 56 °C for 30 min, 75% ethanol, chlorine containing disinfectant and peracetic acid can inactivate SARS-CoV-2 [9]. SARS-CoV-2-S uses the SARS-coronavirus receptor, angiotensin-converting enzyme 2 (ACE2) for entry into host cells. ACE2 is a surface molecule highly expressed in AT2 cells of lung, along with esophageal upper epithelial cells and absorptive enterocytes from ileum and colon which indicated digestive system along with respiratory systems is a potential route for SARS-CoV-2 [10,11]. The expression level of ACE-2 in Asian populations is significantly higher than that in European and American populations, and ACE-2 on male cells is higher than on female cells,

which can partially explain the incidence rate of novel coronavirus pneumonia are higher in male and Asia [12,13].

Transmission

The symptomatic patients with Coronavirus disease are the main disseminators, but the asymptomatic patients should not be underestimated. The current data shows major transmission routes are droplets transmission, contact transmission, and aerosol transmission. fecal-oral transmission cannot be ignored, because the nuclear acid of the SARS-CoV-2 is detected in the fecal samples of patients in the United States and China[14]. Maternal-infant vertical transmission is doubtful-there have been no documented neonates of intrauterine vertical transmission occurring with SARS and MERS[15, 16]. According to existing complete data, amniotic fluid, cord blood, neonatal throat swab, and breastmilk samples from six newborn babies delivered by infected mothers were tested for SARS-CoV-2, and all samples tested negative for the virus. [17].

Clinical presentation of COVID-19

The incubation periods of COVID-19 were 1–14 days, and the mean has been estimated to be 5.2 days (95% confidence interval 4.4 to 6.0) and 97.5% of those who develop symptoms will do so within 10.5 days (95% CI: 7.3 to 15.3) of infection [18]. From the first confirmed child case who was reported in Shenzhen on 20th January 2020 to 6

February 2020, at least 230 COVID-19 cases in children (≤ 18 years)

have been reported in China. The SARS-CoV-2 rapid spread in children suggests it has a strong transmission capacity in special population (neonate, children). SARS-CoV-2 infection can range from asymptomatic infection to severe respiratory distress in neonate and children. However, respiratory distress occurs in children with underlying conditions. One patient had severe malnutrition and survived surgery for congenital heart disease, the other had bilateral hydronephrosis and left-kidney calculi. The clinical course of COVID-19 was generally milder in children than adults. The most common clinical symptoms of COVID-19 included fever, fatigue and dry cough. A few patients showed upper respiratory symptoms such as nasal obstruction, nasal discharge and sore throat. Gastrointestinal symptoms such as abdominal discomfort, vomiting, abdominal pain and diarrhea may also occur. C-reactive protein was normal or temporary upregulation, ALT levels and myocardial enzyme were not

obviously abnormal changes. Chest imaging normalities were present in asymptomatic infected patients. SARS-CoV-2 can be mixed to different pathogen including mycoplasma pneumonia, influenza A, influenza B, RSV and EB virus. The clearance time of SARS-CoV-2 nucleic acid from nasopharyngeal swab were recorded in 3 children, nine days in two patients, 12 days in one patient [19]. Thus far, no deaths have been reported in the children which is similar to SARS [19,20]. Three newborns have been diagnosed up to date who mainly belonged to family cluster cases. One 17 days old neonate diagnosed as COVID-19 infection had fever, cough and vomiting milk. In his family, the housemaid was the earliest case, subsequently, the mother was infected [21]. The second newborn appeared fever on 5 days after birth whose mother also confirmed infected. The third one who was born by the infected mother was silent and diagnosed on 30h after birth by the viral nucleic acid test. Short breath, vomiting milk, cough and fever were present in neonates. The vital signs of those neonates were stable, the disease condition were slightly, there is no severe emergency case until now [19, 21, 22,23].

Diagnosis

Diagnosis of COVID-19 is based on a comprehensive contact and travel history and precise laboratory tests. Current diagnostic tools were the nucleic acid or virus gene tests. Samples included nasopharyngeal swab, sputum, secretion of lower respiratory tract, blood and feces. Nasopharyngeal swab is the most common specimens, however, its detection positive rate is less than 50%. Repeated detection is necessary to improving the positive rate. The positive rate of bronchoalveolar lavage fluid was high, but it is not suitable for most of patients due to increased risk of cross-infection [24,25]

Infection control and Treatment

Neonatologist must wear protective equipment (including hats, goggles, protective suits, gloves, N95 masks, etc.) to resuscitate neonates delivered by confirmed and/or suspected COVID-19 puerperant. If the puerperant is positive for SARS-CoV-2, the neonate must be isolated, then detected SARS-CoV-2 [26].

Early identification and early isolation are imperative for COVID-19 control. COVID-19 neonates should be placed in negative pressure rooms or in rooms in which room exhaust is filtered through high-efficiency particulate air (HEPA) filters with reference to MERS

management[16]. No visiting are allowed for neonates of COVID-19. Treatment mainly depends on adult patients clinical experience due to few cases in children. There is no specific drug treatment for SARS-CoV-2 just like MERS-CoV and SARS-CoV[19,26], Symptomatic and supportive treatment are the mainstay of therapy for patients of SARS-CoV-2 infection including the supply of oxygen, the maintenance of water electrolyte and acid-base balance. The supplement of water and electrolyte should be appropriate, so as to avoid aggravating the pulmonary edema and reduced oxygenation[27]. For newborns with severe acute respiratory distress syndrome, high-dose pulmonary surfactant (PS), inhaled nitric oxide (iNO), high-frequency oscillatory ventilation (HFOV) and extracorporeal membrane lung (ECMO) may be useful. In the United States, A patients' conditions were improved apparently after treatment with nucleoside analogue-remdesivir, but there was just one case, the efficacy needs further verification[28]. Interferon- α 2b nebulization were be applied in MERS-CoV and SARS-CoV, so it could be considered to use in SARS-CoV-2 infection[29,30]. In addition, three potential drug combinations (sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) are candidate repurposable drugs[31]. Moreover, convalescent sera from SARS-CoV-2-recovered patients may be useful for SARS-CoV-2 infection, because of a significant reduction in the mortality following convalescent sera from SARS-recovered patients treatment [32].

Conclusions

COVID-19 can result in asymptomatic to severe illness, Fortunately children without underlying diseases appeared to have mild disease. The disease condition of the neonates were also slightly. Though this new virus come out without specific antiviral drugs treatment, neonatologist need to more virological, epidemiological and clinical data to treat and manage COVID-19.

Conflicts of Interest:

The authors declare that they have no conflict of interest.

Authors' Contributions

Qi Lu and Yuan Shi conceived this review. Qi Lu wrote the manuscript, Yuan Shi revised the manuscript.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*, 2020. 20;382(8):727-733
2. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet*. 2020 15;395(10223):470-473.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 15;395(10223):497-506
4. National Health Commission of the people's Republic of China. Latest developments in epidemic control of 2019-nCoV
5. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020 22;395(10224):565-574.
6. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. *Nature*. 2020 Feb 3. doi: 10.1038/s41586-020-2008-3
7. Giorgi Carmine Ceraolo, Federico M. Giorgi. Genomic variance of the 2019-nCoV coronavirus. *bioRxiv* 2020.02.02.931162; doi: <https://doi.org/10.1101/2020.02.02.931162>
8. Tommy Tsan-Yuk Lam, Marcus Ho-Hin Shum, Hua-Chen Zhu, Yi-Gang Tong, Xue-Bing Ni, Yun-Shi Liao, et al. Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China. *bioRxiv* 2020.02.13.945485; doi: <https://doi.org/10.1101/2020.02.13.945485>
9. National Health Commission of the people's Republic of China, National Administration of Traditional Chinese Medicine. Handbook of Prevention and Treatment of the Pneumonia Caused by the Novel Coronavirus (2019-nCoV) (Trial version 5)
10. Markus Hoffmann, Hannah Kleine-Weber, Nadine Krüger, Marcel Müller, Christian Drosten, Stefan Pöhlmann. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor2 ACE2 and

the cellular protease TMPRSS2 for entry into target cells. *bioRxiv* 2020.01.31.929042; doi: <https://doi.org/10.1101/2020.01.31.929042>

11.Hao Zhang, Zijian Kang, Haiyi Gong, Da Xu, Jing Wang, Zifu Li, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. *bioRxiv* 2020.01.30.927806; doi: <https://doi.org/10.1101/2020.01.30.927806>

12.Zhang Q, Cong M, Wang N, Li X, Zhang H, Zhang K,et al.Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: A case-control study. *Medicine (Baltimore)*. 2018;97(42):e12917.

13.Yu Zhao, Zixian Zhao, Yujia Wang, Yueqing Zhou, Yu Ma, Wei Zuo. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. *bioRxiv* 2020.01.26.919985; doi: <https://doi.org/10.1101/2020.01.26.919985>

14.Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B,et al.Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes.*Emerg Microbes Infect.* 2020;9(1):386-389.

15. Principi N, Bosis S, Esposito S.Effects of Coronavirus Infections in Children. *Emerg Infect Dis.* 2010; 16(2): 183–18815.

16. Zumla A, Hui DS, Perlman S.Middle East Respiratory Syndrome *Lancet.* 2015 5; 386(9997): 995–1007

17.Huijun Chen, Juanjuan Guo, Chen Wang, Fan Luo, Xuechen Yu, Wei Zhang, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *The Lancet* 2020; published online Feb 12.

18. Stephen A. Lauer, Kyra H Grantz, Qifang Bi, Forrest K Jones, Qulu Zheng, Hannah Meredith, et al.The incubation period of 2019-nCoV from publicly reported confirmed cases: estimation and application. *Med Rxiv* 2020. 02. 02. 20020016; doi: <https://doi.org/10.1101/2020.02.02.20020016>

19. Recommendation for the diagnosis and treatment of novel coronavirus infection/ pneumonia in children in Hubei (Trial version 2)

20. A M Li, P C Ng. Severe acute respiratory syndrome (SARS) in neonates and children. Arch Dis Child Fetal Neonatal Ed. 2005;90(6):F461-5.
21. Zeng Lingkong , Tao Xuwei , Yuan Wenhao, Jin Wang, Xin Liu, Zhisheng Liu. First case of neonate infected with novel coronavirus pneumonia in China. Chin J Pediatr ,2020,58(00):E009-E009.13.
22. Jiehao Cai, Xiangshi Wang, Yanling Ge, Aimei Xia, Hailing Chang, He Tian, et al. First case of 2019 novel coronavirus infection in children in Shanghai. Chin J Pediatr, 2020,58: E002-E002.
23. Huiling Deng, Yufeng Zhang, Yi Wang, Feiyu Li. Two cases of 2019 novel coronavirus infection in children. Chin Pediatr Emerg Med , 2020 , 27 (22) : 81-83.
24. Yan Jie, Mingyuan Li, Sun Aihua, Peng Yihong. 2019 novel coronavirus (2019-nCoV) and 2019-nCoV pneumonia. Chin J Microbiol Immunol, 2020,40(00): DOI: 10.3760/cma.j.issn.0254-5101.2020.01.001
25. Zhancheng Gao. Efficient management of novel coronavirus pneumonia by efficient prevention and control in scientific manner. Chin J Tuberc Respir Dis, 2020,43(00): E001-E001
26. Chinese expert consensus on the perinatal and neonatal management for the prevention and control of the 2019 novel coronavirus infection (First edition) Annals of Translational Medicine doi: 10.21037/atm.2020.02.20
27. The Society of Pediatrics, Chinese Medical Association; the Editorial Board, Chinese Journal of Pediatrics. Recommendations for the diagnosis, prevention and control of the 2019 novel coronavirus infection in children (first interim edition) Chin J Pediatr, 2020,58(00):E004-E004.
28. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Jan 31. doi: 10.1056/NEJMoa200119

29. Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al Mutairy E. Ribavirin and interferon- α 2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases. *Antivir Ther.* 2015;20(1):87-91
30. Danesh A, Cameron CM, León AJ, Ran L, Xu L, Fang Y, et al. Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation. *Virology.* 2011 5;409(1):102-12
31. Yadi Zhou, Yuan Hou, Jiayu Shen, Yin Huang, William Martin, Feixiong Cheng. Network-based Drug Repurposing for Human Coronavirus. medRxiv <http://dx.doi.org/10.1101/2020.02.03.20020263>
32. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. *J Infect Dis.* 2015 1;211(1):80-90